Moleculin Biotech, Inc. Legal Fees
Moleculin Biotech, Inc. (MBRX) reported Legal Fees of $200.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2025-03-21
- Moleculin Biotech, Inc. legal fees for fiscal 2024 was $200.00K, a 86.67% decline from fiscal 2023.
- Moleculin Biotech, Inc. legal fees for fiscal 2023 was $1.50M, a 37.50% decline from fiscal 2022.
- Moleculin Biotech, Inc. legal fees for fiscal 2022 was $2.40M.
| Period end | Legal Fees 12 month |
|---|---|
| 2024-12-31 | $200.00K 10-K · filed 2025-03-21 |
| 2023-12-31 | $1.50M 10-K · filed 2025-03-21 |
| 2022-12-31 | $2.40M 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |